North America Hereditary Cancer Testing Market to Reach US$ 3,247.37 Mn at a CAGR of 11.6% in 2027

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. North America Hereditary Cancer Testing Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. North America Hereditary Cancer Testing Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Growing Awareness About Hereditary Cancer

5.2 Market Opportunities

5.2.1 Growing Adoption of Multi-Gene Panel Testing

5.3 Future Trends

5.3.1 Preference for Personalized Medicines

5.4 Impact of Drivers and Restraints

6. North America Hereditary Cancer Testing Market Regional Analysis

6.1 North America Hereditary Cancer Testing Market Overview

6.2 North America Hereditary Cancer Testing Market Revenue 2016-2027 (US$ Million)

6.3 North America Hereditary Cancer Testing Market Forecast Analysis

7. North America Hereditary Cancer Testing Market Analysis – by Diagnosis Type

7.1 Biopsy

7.1.1 Overview
7.1.2 Biopsy: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Imaging

7.2.1 Overview
7.2.2 Imaging: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Hereditary Cancer Testing Market Analysis – by Technology

8.1 Sequencing

8.1.1 Overview
8.1.2 Sequencing: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)

8.2 PCR

8.2.1 Overview
8.2.2 PCR: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)

8.3 Microarray

8.3.1 Overview
8.3.2 Microarray: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)

9. North America Hereditary Cancer Testing Market Analysis – by End User

9.1 Hospital

9.1.1 Overview
9.1.2 Microarray: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)

9.2 Clinics

9.2.1 Overview
9.2.2 Microarray: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)

9.3 Diagnostic Centers

9.3.1 Overview
9.3.2 Microarray: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)

10. North America Hereditary Cancer Testing Market – North America Analysis

10.1 North America

10.1.1 North America Hereditary Cancer Testing Market Breakdown, by Key Country, 2019 and 2027 (%)
10.1.1.1 North America Hereditary Cancer Testing Market – Revenue and Forecast Analysis – by Country
10.1.1.1 US: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1.1 US: North America Hereditary Cancer Testing Market Breakdown, by Diagnosis Type
10.1.1.1.2 US: North America Hereditary Cancer Testing Market Breakdown, by Technology
10.1.1.1.3 US: North America Hereditary Cancer Testing Market Breakdown, by End User

10.1.1.2 Canada: North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.2.1 Canada: North America Hereditary Cancer Testing Market Breakdown, by Diagnosis Type
10.1.1.2.2 Canada: North America Hereditary Cancer Testing Market Breakdown, by Technology
10.1.1.2.3 Canada: North America Hereditary Cancer Testing Market Breakdown, by End User

10.1.1.3 Mexico : North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.3.1 Mexico : North America Hereditary Cancer Testing Market Breakdown, by Diagnosis Type
10.1.1.3.2 Mexico : North America Hereditary Cancer Testing Market Breakdown, by Technology
10.1.1.3.3 Mexico : North America Hereditary Cancer Testing Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. North America Hereditary Cancer Testing Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Biosero Inc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Hologic Inc.

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Koninklijke Philips N.V.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Quest Diagnostics Incorporated

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Myriad Genetics, Inc.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Cancer Genetics Inc.

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Invitae Corporation

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Myogenes

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Strand Life Sciences Pvt. Ltd.

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Pathway Genomics Corporation

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

13.11 CENTOGENE AG

13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments

14. Appendix

14.1 About Business Market Insights